Research on Potential Biomarkers of Prediabetes and Diabetes Based on MALDI-TOF MS Platform.
Condition(s) studied
Investigational drug(s) / intervention(s)
Oral Glucose Tolerance Test: Grouping based on detected oral glucose tolerance test results without any other intervention.
Study summary
Through the MALDI-TOF MS platform, explore the proteomics and peptidomics differences of fasting serum/plasma and urine between non pregnant people with normal glucose tolerance test and prediabetes /diabetes patients, pregnant people with normal glucose tolerance test and pregnant diabetes patients respectively; To explore the role of its proteomics and peptidomics differences in the diagnosis of prediabetes and diabetes, and to establish a new method of differential diagnosis by using the omics data and key characteristic peaks to find potential new diagnostic markers.
Eligibility
Primary outcome measure(s)
- Number and types of proteins/peptides differential characteristic peaks — one year
Obtain the number and types of proteins/peptides differential characteristic peaks between the case group and the control group through data analysis.
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Zhujiang Hospital of Southern Medical University | Guangzhou | Guangdong | Recruiting |
More Zhujiang Hospital trials in China
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT06097065 on ClinicalTrials.gov ↗ ← All trials in China